[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@cp_option Avatar @cp_option CP - Option seller

CP - Option seller posts on X about sanofi, $abbv, $abvx, $sny the most. They currently have XXX followers and X posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks XXXXX% finance XXXXX%

Social topic influence sanofi #28, $abbv #62, $abvx #55, $sny 11.11%, growth 11.11%, the only 11.11%, gems 11.11%, $20b 11.11%, $tak 11.11%, $15b XXXXX%

Top accounts mentioned or mentioned by @phoenix3million @taeyoon43334145 @sehajfund @teslarosa @seedy19tron @wyv_123 @aggregategains @pickingmyown @johnn355

Top assets mentioned Sanofi (SNY) AbbVie Inc (ABBV) Synthetify (SNY)

Top Social Posts

Top posts by engagements in the last XX hours

"$ABVX logical buyers X. Sanofi ($SNY) The Most Logical Buyer Probability : XX% The Logic: Sanofi is the "King of Immunology" (thanks to Dupixent) but they have a massive hole: They don't have a pill. Dupixent is an injection. In the IBD market patients want pills (orals)"
X Link 2025-12-09T00:37Z XXX followers, 1620 engagements

"Financial Capacity: Sanofi has been aggressive in 2025 (acquired Blueprint Medicines in June). They have the cash and the mandate to buy "Growth." X. AbbVie ($ABBV) The "Defensive" Buyer Probability: XX% The Logic: AbbVie owns the IBD market today with Skyrizi and Rinvoq"
X Link 2025-12-09T00:39Z XXX followers, XXX engagements

"@taeyoon43334145 @SehajFund @Phoenix3million @teslarosa $XXX call - 5800 volume $XXX call - 1500 volume Its insane. Definitely not normal. Something is definitely going on. $ABVX"
X Link 2025-12-09T21:03Z XXX followers, 1298 engagements

"The Gap: Sanofis pipeline is heavily reliant on injectables. To compete with AbbVies Rinvoq (a pill) Sanofi needs a high-efficacy oral drug. Abivax is the only one left. The "French Connection":The French gov. often pressuresto acquire local biotech gems to keep the IP"
X Link 2025-12-09T00:38Z XXX followers, XXX engagements

"They generate $20B+ a year from these. The Motivation: Fear. If Sanofi or Pfizer buys Abivax they become a direct threat to AbbVies dominance. AbbVie often buys competitors just to "kill" the threat or control the asset (Defensive M&A)"
X Link 2025-12-09T00:40Z XXX followers, XXX engagements

"The "Inside" Link: As verified earlier Abivaxs new CMO (Fabio Cataldi) previously sold Landos Biopharma to AbbVie. Their new Board Director (Dominik Hchli) was a VP at AbbVie. The company is effectively staffed by ex-AbbVie dealmakers"
X Link 2025-12-09T00:40Z XXX followers, XXX engagements

"3. Takeda ($TAK) The "Desperate" Buyer Probability: XX% The Logic: Takeda is a GI (Gastrointestinal) powerhouse because of Entyvio. Entyvio is an IV/ and its patent cliff is approaching. Takeda is desperate for a successor product to keep their GI division alive"
X Link 2025-12-09T00:42Z XXX followers, XXX engagements

"The Fit: Obefazimod is the perfect "Entyvio 2.0" (safe gut-selective but an oral pill). The Hurdle: Takeda often lacks the massive cash pile ($15B+) that Sanofi or AbbVie has. They might need a partnership first then a buyout"
X Link 2025-12-09T00:42Z XXX followers, XXX engagements

"@seedy19tron Ready to deploy some of the profit on $OVID after buyout. Lets go"
X Link 2025-12-10T03:40Z XXX followers, XXX engagements